Earnings ·
Reports Q3 net loss of $14M and $10M milestone from Novo as SONATA-HCM enrollment completes
LXRXLexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals reported a third-quarter 2026 net loss of $14.0 million, or $0.03 per share, compared to a $12.8 million loss in the prior year period. Total revenues were $11.3 million, driven by a $10.0 million development milestone payment from Novo and $1.2 million in net sales of INPEFA. The company completed enrollment in its pivotal Phase 3 SONATA-HCM study with 542 patients, expecting top-line data in Q1 2027. Additionally, positive safety data from the STENO1 study supports the planned resubmission of the ZYNQUISTA NDA for type 1 diabetes in early 2027. Lexicon Pharmaceuticals is a biopharmaceutical company developing cardiometabolic therapies.